Strong H1 2026 results with 6% revenue and 14% EBITDA growth, led by Specialty Chemicals. Outlook for 2026 confirmed with sales expected to reach €600m and EBITDA €126m, supported by new plant investments and US expansion.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.